An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia
Clinical trial NCT05304767 · COMPLETED
Trial details
- NCT number
- NCT05304767
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-03-07
- Primary completion
- 2026-03-25
- Enrollment
- 290
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.